The CLCNKA antibody is designed to target the CLC-Ka protein, a member of the CLC family of chloride channels encoded by the *CLCNKA* gene. CLC-Ka, predominantly expressed in the kidney's thick ascending limb of Henle and inner ear, plays a critical role in renal electrolyte transport and urine concentration. It functions in conjunction with its beta-subunit barttin (encoded by *BSND*), which regulates its trafficking and activity. Dysregulation or mutations in *CLCNKA* are linked to Bartter syndrome type IV, a rare inherited renal disorder characterized by salt wasting, hypokalemia, and metabolic alkalosis. CLCNKA antibodies are essential tools in research to study the expression, localization, and functional roles of this channel in physiological and pathological contexts. They are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to investigate kidney development, ion homeostasis, and mechanisms underlying tubular disorders. Additionally, these antibodies aid in exploring potential therapeutic targets for conditions like hypertension, renal fibrosis, and congenital kidney diseases. Recent studies also highlight their utility in animal models to dissect CLC-Ka's interaction with diuretics or genetic modifiers. Overall, CLCNKA antibodies provide crucial insights into chloride channel biology and their implications in human health.